TG Therapeutics
Employee Participants19
Total Rating339
Revenue$0
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. Read More
Headquarters 3020 Carrington Mill Blvd., Morrisville, NC 27560-5435, USA
Website http://tgtherapeutics.com
Phone Number 1-877-TGTXINC
75/100